Cargando…

Synergistic anticancer effects of ruxolitinib and calcitriol in estrogen receptor-positive, human epidermal growth factor receptor 2-positive breast cancer cells

The Janus kinase (JAK)1 and JAK2 inhibitor, ruxolitinib, and the active form of vitamin D (calcitriol) were previously reported to possess anticancer effects in breast cancer. The present study investigated the combined effects of ruxolitinib and calcitriol on an estrogen receptor (ER)-positive, hum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lim, Seung Taek, Jeon, Ye Won, Gwak, Hongki, Kim, Se Young, Suh, Young Jin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5865997/ https://www.ncbi.nlm.nih.gov/pubmed/29436642 http://dx.doi.org/10.3892/mmr.2018.8580

Ejemplares similares

Effects of Ruxolitinib and Calcitriol Combination Treatment on Various Molecular Subtypes of Breast Cancer
por: Schneider, Jean, et al.
Publicado: (2022)

Clinical Implications of Serum 25-Hydroxyvitamin D Status after 5-Year Adjuvant Endocrine Therapy for Late Recurrence of Hormone Receptor-positive Breast Cancer
por: Lim, Seung Taek, et al.
Publicado: (2020)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Volume replacement with diced acellular dermal matrix in oncoplastic breast-conserving surgery: a prospective single-center experience
por: Gwak, Hongki, et al.
Publicado: (2020)

Clinical Impact of Primary Prophylactic Pegfilgrastim in Breast Cancer Patients Receiving Adjuvant Docetaxel-Doxorubicin-Cyclophosphamide Chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2020)

Nomogram for the Prediction of Biochemical Incomplete Response in Papillary Thyroid Cancer Patients
por: Lim, Seung Taek, et al.
Publicado: (2021)

Anti-tumor efficacy of fulvestrant in estrogen receptor positive gastric cancer
por: Yi, Jun Ho, et al.
Publicado: (2014)

Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
por: KIM, JINKYOUNG, et al.
Publicado: (2016)

YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior
por: Jeon, Youngsic, et al.
Publicado: (2021)

COVID-19 Prevention Guidance and the Incidence of Febrile Neutropenia in Patients with Breast Cancer Receiving TAC Chemotherapy with Prophylactic Pegfilgrastim
por: Gwak, Hongki, et al.
Publicado: (2022)

Clinical utilization of long-acting granulocyte colony-stimulating factor (pegfilgrastim) prophylaxis in breast cancer patients with adjuvant docetaxel-cyclophosphamide chemotherapy
por: Jeon, Ye Won, et al.
Publicado: (2021)

Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer
por: Kim, Sangmin, et al.
Publicado: (2021)

Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2023)

Schisandrol A Exhibits Estrogenic Activity via Estrogen Receptor α-Dependent Signaling Pathway in Estrogen Receptor-Positive Breast Cancer Cells
por: Lee, Dahae, et al.
Publicado: (2021)

The anticancer activity of genistein is increased in estrogen receptor beta 1-positive breast cancer cells
por: Jiang, Hua, et al.
Publicado: (2018)

Characteristics and Prognosis of Estrogen Receptor Low-Positive Breast Cancer
por: Kim, Min Chong, et al.
Publicado: (2022)

Expression of Androgen Receptor in Estrogen Receptor–positive Breast Cancer
por: Agrawal, Anil, et al.
Publicado: (2016)

Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival
por: Jeon, Ye Won, et al.
Publicado: (2015)

Leptin as a Potential Target for Estrogen Receptor-Positive Breast Cancer
por: Yom, Cha Kyong, et al.
Publicado: (2013)

Prognostic value of tumor-infiltrating lymphocytes in estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer
por: Honda, Chikako, et al.
Publicado: (2021)

The origins of estrogen receptor alpha-positive and estrogen receptor alpha-negative human breast cancer
por: Allred, D Craig, et al.
Publicado: (2004)

Activity of Estrogen Receptor β Agonists in Therapy-Resistant Estrogen Receptor-Positive Breast Cancer
por: Datta, Jharna, et al.
Publicado: (2022)

Relative Survival Benefit by Hormonal Receptor Status of Adding Trastuzumab to Neoadjuvant Chemotherapy in Breast Cancer Patients
por: Schneider, Jean, et al.
Publicado: (2020)

Molecular portraits and trastuzumab responsiveness of estrogen receptor-positive, progesterone receptor-positive, and HER2-positive breast cancer
por: Zhao, Shen, et al.
Publicado: (2019)

Combinations of Calcitriol with Anticancer Treatments for Breast Cancer: An Update
por: Segovia-Mendoza, Mariana, et al.
Publicado: (2021)

Outcomes of Estrogen Receptor Negative and Progesterone Receptor Positive Breast Cancer
por: Chan, Melissa, et al.
Publicado: (2015)

Mouse models of estrogen receptor-positive breast cancer
por: Mohibi, Shakur, et al.
Publicado: (2011)

Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis
por: Porras, Lucas, et al.
Publicado: (2021)

Genes Dysregulated to Different Extent or Oppositely in Estrogen Receptor-Positive and Estrogen Receptor-Negative Breast Cancers
por: Zhou, Xianxiao, et al.
Publicado: (2013)

Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers
por: Chiu, Jen-Hwey, et al.
Publicado: (2017)

Estrogen receptor α is involved in the regulation of ITGA8 methylation in estrogen receptor-positive breast cancer
por: Wu, Jingxun, et al.
Publicado: (2020)

Calcitriol restores antiestrogen responsiveness in estrogen receptor negative breast cancer cells: A potential new therapeutic approach
por: Santos-Martínez, Nancy, et al.
Publicado: (2014)

Factors That Predict Biological Aggressiveness in Estrogen Receptor–Positive / Human Epidermal Growth Factor Receptor 2–Negative / Lymph Node–Negative Breast Cancer
por: Arthur, Lauren E., et al.
Publicado: (2020)

Phase II study of apatinib plus exemestane in estrogen receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer
por: Tan, Aihua, et al.
Publicado: (2023)

Bicalutamide plus Aromatase Inhibitor in Patients with Estrogen Receptor‐Positive/Androgen Receptor‐Positive Advanced Breast Cancer
por: Lu, Qianyi, et al.
Publicado: (2019)

Expression of T-Lymphocyte Markers in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
por: Lee, Changro, et al.
Publicado: (2016)

Estrogen receptor-β: why may it influence clinical outcome in estrogen receptor-α positive breast cancer?
por: Shupnik, Margaret A
Publicado: (2007)

Estrogen receptor coregulator binding modulators (ERXs) effectively target estrogen receptor positive human breast cancers
por: Raj, Ganesh V, et al.
Publicado: (2017)

Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer
por: Xia, Song, et al.
Publicado: (2022)

Impact of palbociclib combinations on treatment of advanced estrogen receptor-positive/human epidermal growth factor 2-negative breast cancer
por: Boér, Katalin
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_j1h1atd60jt18u5qg3vevhbl5p